U.S. COMPANY FILING
ALNYLAM PHARMACEUTICALS, INC. — Form 10-K filed 2026-02-12
Filing text preview
Alnylam Pharmaceuticals reported first annual profitability in FY2025 with revenue of $2.99 billion and net income of $316 million, driven by AMVUTTRA growth. The company launched 'Alnylam 2030' strategy targeting 25%+ revenue CAGR through 2030. Risks include government subpoena, competition, and convertible notes obligations.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record